Wolfgang Miesbach: Octreotide as a First‑Line Systemic Option in VWD Patients With Angiodysplasia‑Related GI Bleeding
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Could octreotide become a first‑line systemic option in VWD patients with angiodysplasia‑related GI bleeding?
Great talk by Sophie Susen at the EHA meeting in Florence on angiodysplasia‑related GI bleeding and the implications of the OCEAN trial for VWD.
OCEAN trial:
- Multicenter RCT in 62 patients with transfusion‑dependent angiodysplasia‑related anemia, Octreotide LAR 40 mg q4w vs standard care.
- About 50% reduction in transfusion requirements (11.0 vs 21.2 units), alongside fewer endoscopic procedures and hospitalizations, with a generally favourable safety profile.
What octreotide actually does
Octreotide, a long‑acting somatostatin analogue, reduces splanchnic blood flow and portal pressure, improves platelet aggregation, and exerts anti‑angiogenic effects via inhibition of VEGF and other growth factors.
This mechanistic profile makes it particularly attractive for chronic bleeding from GI angiodysplasia.
What this could mean for VWD
Even though VWD patients were not included in OCEAN, these robust data provide the best evidence we currently have for systemic therapy in angiodysplasia‑related bleeding and strongly support octreotide as a potential first‑line systemic option in this setting.
Case reports and small series in VWD already suggest benefit, but dedicated prospective trials in VWD with angiodysplasia are urgently needed to define efficacy, safety, and optimal positioning in future treatment algorithms.”
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers